Novo Nordisk invests $1.05B in Brazil factory to boost GLP-1 drug production, including Wegovy and Ozempic, creating 600 jobs ...

An ex-manager for Novo Nordisk Inc. reached a settlement in her lawsuit alleging the healthcare company failed to accommodate her disabilities, retaliated against her, and wrongfully terminated her.

Obesity drug market heats up in India; Novo Nordisk advances Wegovy launch from 2026 to coming months to challenge Eli ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...

The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has been approved for early trials in China and the U.S.

Bloomington Mayor Mboka Mwilambwe, left, and his challenges Cody Hendricks and Dan Brady spoke at Monday's candidates night with local unions. The union delegates endorsed Hendricks. This is Part 1 of ...

No­vo Nordisk is re­or­ga­niz­ing its re­search and ear­ly de­vel­op­ment unit in an ef­fort to “fu­ture-proof the or­ga­ni­za­tion” and “sig­nif­i­cant­ly in­crease ...